DigestRedComo funciona
Red
/
Empresas
Pu
No verificado

PureTech Health plc

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

66 Comunicados de prensa

Ver todos los comunicados de prensa
21/09/2026
Multimedia
Mercado laboral
Industria
Oncología
Psiquiatría
Salud
Higiene alimentaria
Medicina - Varios
Farmacéutica
Biotecnología
PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS)
Fuente
PureTech Health plc
Editor
Business Wire
1.00
0
09/09/2026
Industria
Biotecnología
Psiquiatría
Salud
Farmacéutica
Medicina - Varios
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
Fuente
PureTech Health plc
Editor
Business Wire
1.00
0
04/09/2026
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Biotecnología
Farmacéutica
Salud
PureTech Health: Notice of Half-Yearly Results
Fuente
PureTech Health plc
Editor
Business Wire
1.00
0
13/07/2026
Industria
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Fuente
PureTech Health plc
Editor
Business Wire
1.00
0
02/07/2026
Industria
Ciencia
Higiene alimentaria
Medicina - Varios
Biotecnología
Sanidad
Salud
Farmacéutica
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
Fuente
PureTech Health plc
Editor
Business Wire
1.00
0
10/06/2026
Biotecnología
Salud
Ciencia
Farmacéutica
PureTech Health: Results of Annual General Meeting
Fuente
PureTech Health plc
Editor
Business Wire
1.00
0
09/06/2026
Industria
Salud
Sanidad
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
Fuente
PureTech Health plc
Editor
Business Wire
1.00
0
13/05/2026
Industria
Salud
Farmacéutica
PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference
Fuente
PureTech Health plc
Editor
Business Wire
1.00
0
29/04/2026
Mercado de valores
Web y redes sociales
Telefonía
Técnica
Medicina - Varios
Software
Biotecnología
Sanidad
Farmacéutica
Salud
Oncología
PureTech Announces Annual Results for Year Ended December 31, 2025
Fuente
PureTech Health plc
Editor
Business Wire
1.00
0
29/04/2026
Salud
Sanidad
Ciencia
Farmacéutica
Biotecnología
PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange
Fuente
PureTech Health plc
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0